[Application of pelvic sentinel lymph node tracing technique in radical prostatectomy].

Zhonghua Nan Ke Xue

Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.

Published: August 2021

AI Article Synopsis

  • Pelvic lymph node dissection is a crucial part of radical prostatectomy (RP) but can lead to overtreatment and longer surgery times for patients with intermediate- or high-risk prostate cancer (PCa).
  • The concept of sentinel lymph nodes (SLN) refers to the first node that cancer spreads to, which is important for effective lymph node dissection.
  • This review examines the challenges and advancements in using SLN tracing techniques during radical prostatectomy, highlighting the issues with lymphatic drainage pathways and current tracing technologies.

Article Abstract

Pelvic lymph node dissection is an important step in radical prostatectomy (RP). Extended pelvic lymph node dissection (ePLND), currently employed for patients with intermediate- or high-risk PCa, may lead to overtreatment, prolong the operation time, and increase the risks of complications. Sentinel lymph node (SLN) is defined as the first metastasis lymph node from the primary tumor. In addition, SLN distribution is essential for overall lymph node dissection. However, due to the complex and diverse lymphatic drainage pathways and the inaccuracy of lymphatic tracing technology, SLN distribution and dissection have always been controversial. This review focuses on the application of pelvic SLN tracing technique in radical prostatectomy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

lymph node
24
node dissection
12
sentinel lymph
8
tracing technique
8
technique radical
8
pelvic lymph
8
radical prostatectomy
8
sln distribution
8
lymph
6
node
6

Similar Publications

Cisplatin, a platinum-based chemotherapeutic agent, can be used to treat cervical cancer (CC), but cisplatin resistance is increased during the cisplatin treatment. Long non-coding RNA PGM5-AS1 reportedly participates in CC tumorigenesis; however, its role in CC patients with cisplatin resistance has not been revealed. The present aimed to examine the role of PGM5-AS1 in modulating cisplatin resistance in CC.

View Article and Find Full Text PDF

This study aimed to investigate the correlation between baseline MRI features and baseline carcinoembryonic antigen (CEA) expression status in rectal cancer patients. A training cohort of 168 rectal cancer patients from Center 1 and an external validation cohort of 75 rectal cancer patients from Center 2 were collected. A nomogram was constructed based on the training cohort and validated using the external validation cohort to predict high baseline CEA expression in rectal cancer patients.

View Article and Find Full Text PDF

Relationship between clinical features and distant metastases in rectal cancer predicted based on a nomogram: a retrospective cohort study.

Sci Rep

December 2024

Department of General Surgery, Chifeng Municipal Hospital, Inner Mongolia Medical University, Inner Mongolia, 024000, People's Republic of China.

Rectal cancer is a prevalent global malignancy. Recurrence and metastasis significantly impact patient survival over the long term. This study aims to identify independent risk factors associated with distant metastases in rectal cancer (RC) patients and develop a prognostic columnar-line diagram.

View Article and Find Full Text PDF

PrPc is expressed in various tumors and is associated with cancer progression, but previous studies have shown conflicting results regarding its relationship with patient prognosis-potentially due to differences in the antibodies used. This study aimed to clarify the relationship between PrPc expression and primary esophageal squamous cell carcinoma (ESCC) and primary hepatocellular carcinoma (HCC) using a novel anti-PrPc antibody, 4AA-m, noted for its high specificity and sensitivity. We used flow cytometry to detect PrPc expression in ESCC and HCC cell lines.

View Article and Find Full Text PDF

Chronic lymphocytic leukemia (CLL) is prevalent in adults and is characterized by the accumulation of mature B cells in the blood, bone marrow, lymph nodes, and spleens. Recent progress in therapy and the introduction of targeted treatments [inhibitors of Bruton's tyrosine kinase (BTKi) or inhibitor of anti-apoptotic B-cell lymphoma-2 (Bcl-2i) protein (venetoclax)] in place of chemoimmunotherapy have significantly improved the outcomes of patients with CLL. These advancements have shifted the importance of traditional predictive markers, leading to a greater focus on resistance genes and reducing the significance of mutations, such as TP53 and del(17p).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!